Clinical significance and molecular mechanism of angiotensin-converting enzyme 2 in hepatocellular carcinoma tissues

References

• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer. 2021;148(5):1051–1065.
   PubMed Web of Science ®Google Scholar
• Rushing BR, Selim MI. Aflatoxin B1: a review on metabolism, toxicity, occurrence in food, occupational exposure, and detoxification methods. Food Chem Toxicol. 2019;124:81–100.
   PubMed Web of Science ®Google Scholar
• Duan F, Wu H, Jia D, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis. J Hepatol. 2018;68(6):1191–1202.
   PubMed Web of Science ®Google Scholar
• Seehawer M, Heinzmann F, D’Artista L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018;562(7725):69–75.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Liu X, et al. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nat Commun. 2018;9(1):1572.
   PubMedGoogle Scholar
• Fan C, Lu W, Li K, et al. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients. Front Med (Lausanne). 2020;7:563893.
   PubMed Web of Science ®Google Scholar
• Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228–248.
   PubMed Web of Science ®Google Scholar
• Xu J, Fan J, Wu F, et al. The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: pleiotropic Roles in Cancer. Front Physiol. 2017;8:276.
   PubMed Web of Science ®Google Scholar
• Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, et al. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Mayo Clin Proc. 2020;95(6):1222–1230.
   PubMed Web of Science ®Google Scholar
• Nair MG, Prabhu JS, Ts S. High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. Cancer Treat Res Commun. 2021;27:100321.
   PubMedGoogle Scholar
• Yu C, Tang W, Wang Y, et al. Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett. 2016;376(2):268–277.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637.
   PubMed Web of Science ®Google Scholar
• Stewart CA, Gay CM, Ramkumar K, et al. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv:Preprint Serv Biol. 2020.
   Google Scholar
• Zhang Z, Li L, Li M, et al. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. Comput Struct Biotechnol J. 2020;18:2438–2444.
   PubMed Web of Science ®Google Scholar
• Feng H, Wei X, Pang L, et al. Prognostic and Immunological Value of Angiotensin-Converting Enzyme 2 in Pan-Cancer. Front Mol Biosci. 2020;7:189.
   PubMed Web of Science ®Google Scholar
• Ye G, Qin Y, Lu X, et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. Biochem Biophys Res Commun. 2015;459(1):18–23.
   PubMed Web of Science ®Google Scholar
• Dai YJ, Hu F, Li H, et al. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. Ann Transl Med. 2020;8(7):481.
   PubMed Web of Science ®Google Scholar
• Zhang L, Luo B, Dang YW, et al. The clinical significance of endothelin receptor type B in hepatocellular carcinoma and its potential molecular mechanism. Exp Mol Pathol. 2019;107:141–157.
   PubMed Web of Science ®Google Scholar
• Athar A, Füllgrabe A, George N, et al. ArrayExpress update - from bulk to single-cell expression data. Nucleic Acids Res. 2019;47(D1):D711–d5.
   PubMed Web of Science ®Google Scholar
• Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3(9):1724–1735.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lu S, Li T, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019;38(1):173.
   PubMedGoogle Scholar
• Feng Y, Wan H, Liu J, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 2010;23(4):941–948.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhang R, Yao W, et al. Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med. 2009;217(2):123–131.
   PubMed Web of Science ®Google Scholar
• Zong H, Yin B, Zhou H, et al. Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. Tumour Biol. 2015;36(7):5171–5177.
   PubMedGoogle Scholar
• Qian YR, Guo Y, Wan HY, et al. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep. 2013;29(6):2408–2414.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wen Q, Li SF, et al. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget. 2016;7(31):50612–50623.
   PubMedGoogle Scholar
• Ashida R, Okamura Y, Ohshima K, et al. CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma. Cancer Genomics Proteomics. 2017;14(6):445–453.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhou L, Zheng S. Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma. PeerJ 2020;8:e8930.
   PubMed Web of Science ®Google Scholar
• Pang YY, Li JD, Gao L, et al. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med. 2020;9(21):8004–8019.
   PubMed Web of Science ®Google Scholar
• Shi M, Dai WQ, Jia RR, et al. APC(CDC20)-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma. Cancer Lett. 2021;496:144–155.
   PubMed Web of Science ®Google Scholar
• Feng Y, Ni L, Wan H, et al. Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep. 2011;26(5):1157–1164.
   PubMed Web of Science ®Google Scholar